- Home
- ESCA vs PBYI Comparison
ESCA vs PBYI Comparison
Compare ESCA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESCA
- PBYI
- Stock Information
- Founded
- ESCA 1922
- PBYI 2010
- Country
- ESCA United States
- PBYI United States
- Employees
- ESCA N/A
- PBYI N/A
- Industry
- ESCA Recreational Games/Products/Toys
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ESCA Consumer Discretionary
- PBYI Health Care
- Exchange
- ESCA Nasdaq
- PBYI Nasdaq
- Market Cap
- ESCA 167.7M
- PBYI 171.7M
- IPO Year
- ESCA N/A
- PBYI N/A
- Fundamental
- Price
- ESCA $12.55
- PBYI $4.64
- Analyst Decision
- ESCA
- PBYI Strong Buy
- Analyst Count
- ESCA 0
- PBYI 1
- Target Price
- ESCA N/A
- PBYI $7.00
- AVG Volume (30 Days)
- ESCA 11.4K
- PBYI 648.1K
- Earning Date
- ESCA 10-23-2025
- PBYI 11-06-2025
- Dividend Yield
- ESCA 4.86%
- PBYI N/A
- EPS Growth
- ESCA 10.02
- PBYI 434.29
- EPS
- ESCA 0.92
- PBYI 0.97
- Revenue
- ESCA $241,492,000.00
- PBYI $238,062,000.00
- Revenue This Year
- ESCA N/A
- PBYI N/A
- Revenue Next Year
- ESCA N/A
- PBYI N/A
- P/E Ratio
- ESCA $13.40
- PBYI $4.76
- Revenue Growth
- ESCA N/A
- PBYI 8.63
- 52 Week Low
- ESCA $11.74
- PBYI $2.32
- 52 Week High
- ESCA $16.99
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- ESCA 48.45
- PBYI 49.99
- Support Level
- ESCA $12.31
- PBYI $4.49
- Resistance Level
- ESCA $13.05
- PBYI $5.22
- Average True Range (ATR)
- ESCA 0.40
- PBYI 0.26
- MACD
- ESCA -0.01
- PBYI -0.12
- Stochastic Oscillator
- ESCA 35.29
- PBYI 22.33
About ESCA Escalade Incorporated
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are North America, Europe and others out of which a substantial part of the revenue is generated from North America region.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.